Reference entry · Actin-binding peptide fragment
TB-500
Also known as: Thymosin β-4 fragment · Tβ4-related peptide
- Class
- Actin-binding peptide fragment
- Primary targets (literature)
- Actin cytoskeleton, cell migration (preclinical literature)
- Regulatory context
- Not FDA-approved. TB-500 is a research-catalog designation; identity must be confirmed per batch.
Overview
TB-500 commonly refers to a fragment or analog related to thymosin beta-4 actin-binding biology. Catalog naming is inconsistent — full-length Tβ4, fragments, and mislabeled products all appear in commerce.
Mechanism in research literature
Thymosin beta-4 literature centers on actin sequestration and cell migration in wound-healing and tissue-repair models. Fragment products sold as TB-500 require independent sequence confirmation.
Common research focus areas
- Cell migration and wound-closure assays
- Actin cytoskeleton dynamics
- Sequence verification vs. full-length Tβ4
- Catalog mislabeling risk
Full literature roundup
Read the cited research summary
TB-500 is associated with thymosin beta-4 biology. A look at the actin-binding research context and the gaps in human evidence.
TB-500 research roundup · 6 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.